NCT03926143

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.

Detailed description

The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	BAY94-9343 (Anetumab ravtansine)	BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies

Timeline

• Start date: 2019-06-03
• Primary completion: 2022-05-18
• Completion: 2022-05-18
• First posted: 2019-04-24
• Last updated: 2023-08-04
• Results posted: 2023-08-04

Locations

7 sites across 4 countries: United States, France, Italy, Poland

Regulatory

• FDA-regulated drug study